Scientists in Thailand have developed a faster, cheaper way to manufacture powerful flu antibodies by growing them inside plants instead of using traditional pharmaceutical factories. Researchers from Chulalongkorn University and Thailand's National Center for Genetic Engineering and Biotechnology successfully produced a broad-spectrum influenza antibody called CR9114 in Nicotiana benthamiana plants, demonstrating that plant-based manufacturing could revolutionize how quickly we respond to emerging viral threats. Why This Matters for Future Pandemics? Influenza remains one of the world's most persistent infectious threats, responsible for hundreds of thousands of deaths annually. The real danger lies in avian flu strains like H5N1 and H7N9, which typically circulate among birds but can occasionally jump to humans, sometimes causing severe disease and death. Recent outbreaks have heightened concerns that new strains could spark future pandemics. Traditional vaccine and antibody manufacturing takes monthsâtime we may not have during an outbreak. The Thai research team focused on CR9114 because it targets a highly conserved region of the influenza virus known as the hemagglutinin stem, a part that changes very little across many influenza strains, making it potentially protective against a wide range of viruses. How Plants Became Antibody Factories Instead of using expensive mammalian cell culture systems commonly used in pharmaceutical manufacturing, the researchers inserted genetic instructions for the CR9114 antibody directly into Nicotiana benthamiana plants. Within just four days, the plant leaves began producing antibody molecules at impressive levels. The plant tissue produced approximately 600 micrograms of antibody per gram of fresh leaf material, demonstrating efficient production. After extraction and purification, laboratory analysis confirmed that the plant-produced antibody assembled correctly into a complete human immunoglobulin G (IgG) antibody structure, including the expected heavy and light chains. Testing Against Real Flu Viruses The team then tested whether the plant-produced antibody could recognize and neutralize actual influenza viruses. Laboratory experiments confirmed that the antibody strongly bound to the hemagglutinin protein of an H5N1 influenza virus strain. Further testing evaluated the antibody against two important avian influenza strains linked to human infections: A/Jiangsu/NJ210/2023 (H5N1) and A/Gansu/23277/2019 (H7N9). The results showed particularly strong neutralization of the H5N1 virus, indicating that the antibody was highly effective against this dangerous strain. The antibody also neutralized the H7N9 virus, although the activity was somewhat lowerâa difference scientists note is expected due to structural variations among influenza virus groups. Ways Plant-Based Manufacturing Could Change Pandemic Response - Speed of Production: Antibodies can be produced in five to seven days using plants, compared to weeks or months with traditional bioreactor systems, allowing rapid response during health emergencies. - Cost Efficiency: Plant-based systems are significantly less expensive than traditional pharmaceutical production methods, making antiviral therapies more affordable and accessible globally. - Scalability: Large quantities of therapeutic antibodies could be produced rapidly using agricultural facilities rather than expensive bioreactors, leveraging existing farming infrastructure during crises. - Enhanced Immune Function: Scientists can modify the antibody's sugar molecules, known as glycosylation patterns, which can enhance immune activity and improve how the antibody functions in the body. The findings demonstrate that plant-based biotechnology can successfully produce a powerful influenza-neutralizing antibody while preserving its structural integrity and antiviral activity. These results highlight the potential of plant molecular pharming as a rapid and scalable platform for producing antiviral therapies, strengthening global preparedness for future influenza outbreaks and possible pandemics. The study was published in the peer-reviewed journal Vaccines and involved collaboration between researchers at Chulalongkorn University's Faculty of Pharmaceutical Sciences, Baiya Phytopharm Co., Ltd., and Thailand's National Center for Genetic Engineering and Biotechnology. As influenza viruses continue to mutate and new strains emerge, having a manufacturing system that can produce protective antibodies in days rather than months could be the difference between containing an outbreak and facing a global health crisis. This Thai breakthrough suggests that the future of pandemic preparedness may grow in greenhouses rather than laboratories.
